Morgan Stanley Direct Lending Fund (MSDL) Q4 2025 Earnings Call Highlights: Navigating Economic ...

This article first appeared on GuruFocus.

Net Investment Income: $0.49 per share, compared to $0.50 per share in the prior quarter. Distribution: $0.45 per share for Q1 2026, a $0.05 reduction from the prior quarter. Portfolio Total: $3.8 billion at fair value. Weighted Average Yield: 9.3% at cost and 9.5% at fair value. Total Investment Income: $96.6 million, down from $99.7 million in the previous quarter. Total Expenses: $54.2 million, down from $56 million in the prior quarter. Net Assets: $1.75 billion. NAV per Share: $20.26, compared to $20.41 in the prior period. Debt-to-Equity Ratio: 1.20x, up from 1.17x in the previous quarter. Repurchase Program: $9 million worth of shares repurchased below NAV. Joint Venture Equity Commitment: $250 million, with $200 million committed from MSDL. Spillover Income: Approximately $0.85 as of December 31, 2025.

Warning! GuruFocus has detected 6 Warning Signs with MSDL. Is MSDL fairly valued? Test your thesis with our free DCF calculator.

Release Date: February 27, 2026

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

MSDL generated solid performance in the fourth quarter with net investment income of $0.49 per share. The portfolio continues to perform well with limited contributions from payment in kind and other income. MSDL's borrowers have shown resilience despite economic challenges, with underperformance being isolated and not systemic. The fund benefits from being part of the broader Morgan Stanley platform, providing immense resources for underwriting and portfolio management. MSDL successfully closed a joint venture that is expected to be accretive to net investment income, with the JV already close to 50% ramped.

Negative Points

MSDL's portfolio yield has contracted since the late 2023 peak, although the contraction has decelerated. The Board declared a distribution of $0.45 per share for Q1 2026, a $0.05 reduction from the prior quarter. Total investment income decreased to $96.6 million from $99.7 million in the previous quarter due to recent Fed rate cuts. Non-accruals ticked up modestly, with some underperformance in a small number of portfolio companies. The weighted average yield on debt and income-producing investments declined by roughly 40 basis points quarter-over-quarter.

Q & A Highlights

Q: When considering capital allocation, what do you find most compelling between deploying capital and repurchasing shares, and how do you view leverage in this environment? A: Michael Occi, CEO: We balance multiple capital allocations, finding value in both deploying capital and share repurchases. Leverage is a factor in deal deployment, and we continue to find compelling opportunities in the market. Our buyback program is robust, with $9 million repurchased in Q4, and our Board has renewed the program for up to $100 million.

繼續閱讀

Q: Can you provide insight into the pace and trajectory of ramping the new joint venture (JV)? A: Michael Occi, CEO: The JV has a total equity commitment of $250 million, with $200 million from MSDL. We've already called nearly half of that. The goal is to scale to $700 million in assets over four to six quarters, maintaining the same investment strategy as MSDL.

Q: Are there any concerns about the dental space or specific sectors within healthcare, given recent non-accruals? A: Michael Occi, CEO: The portfolio is generally healthy, but we've seen some weakness in dental roll-ups and logistics. These are the main industry-related underperformers, but our exposure is limited, and other underperformance is idiosyncratic.

Q: What is the expected long-term allocation to the new JV, and how does it impact the overall portfolio? A: Michael Occi, CEO: The JV's $200 million equity commitment represents a 5% allocation relative to the total portfolio. We expect it to provide economic upside potential for MSDL, with half of the capital already called.

Q: How confident are you in maintaining the current dividend level through the rate cycle? A: Michael Occi, CEO: The $0.49 NII baseline is impacted by Fed rate cuts, but the JV can provide incremental ROE and NII. While we can't fully bulletproof the dividend level, we feel confident about its medium-term sustainability based on current variables.

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

查看留言